OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation
Launched by ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND · Feb 22, 2007
Trial Information
Current as of September 02, 2025
Completed
Keywords
ClinConnect Summary
Introduction Total (or near-total) thyroidectomy followed by TSH-stimulated administration of large activities of 131-iodine (131I) is the treatment of choice for DTC \[1-3\]. The serum thyroglobulin (Tg) measurement during hypothyroidism, just before radioiodine thyroid ablation, has proved to be effective for predicting persistent/recurrent disease \[4-8\]. Recently recombinant human TSH (rhTSH) showed to be safely employed instead of thyroxine (T4) withdrawal (offT4) to prepare patients for radioiodine ablation \[9-10\]. However, the Tg level are measured 48 hours after radioiodine admin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hiostologically proved DTC (M0)
- Exclusion Criteria:
- • Preoperative metastasis
About Oncology Institute Of Southern Switzerland
The Oncology Institute of Southern Switzerland (IOSI) is a leading clinical research organization dedicated to advancing cancer treatment and improving patient outcomes through innovative research. Based in the heart of southern Switzerland, IOSI specializes in conducting high-quality clinical trials across various oncology disciplines, collaborating with esteemed academic institutions and healthcare providers. With a commitment to rigorous scientific standards and ethical practices, IOSI aims to facilitate the development of novel therapeutic approaches, fostering a patient-centered environment that prioritizes safety and efficacy in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Luca Giovanella, MD
Principal Investigator
Oncology Institute of Southern Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials